NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...

Scotiabank analyst George Farmer maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today and set a price target ...

Scotiabank analyst George Farmer raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $47 from $35 and keeps an Outperform rating on ...

Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...

Santhera Pharmaceuticals gains approval in China for Agamree, the first Duchenne muscular dystrophy therapy available for ...

On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in ...

I Squared Capital has started due diligence on Hong Kong-listed HKBN Ltd., people familiar with the matter said, as the US ...